Scientific Sessions 2024  /  Redefining Arrhythmia Treatment: Pushing Boundaries  /  Discussant: BRAIN AF
Logo

American Heart Association

  112
  0

Final ID:

Discussant: BRAIN AF

  • Hankey, Graeme  ( UNIVERSITY WESTERN AUSTRALIA , Perth , Western Australia , Australia )
  • Hylek, Elaine  ( BOSTON UNIVERSITY , Boston , Massachusetts , United States )
  • Kamel, Hooman  ( Weill Cornell Medicine , New York , New York , United States )
    • Author Disclosures:
    Graeme Hankey: No Answer | Elaine Hylek: No Answer | Hooman Kamel: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Redefining Arrhythmia Treatment: Pushing Boundaries

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
Discussant: OPTION

Patel Manesh

Discussant: VANISH2

Tedrow Usha

More abstracts from these authors:
The Trouble with ESUS: What do the studies tell us? Where do we do from here?

Kamel Hooman, Messe Steven

Atrial Cardiopathy and Cryptogenic Stroke

Kamel Hooman

You have to be authorized to contact abstract author. Please, Login
Not Available